Barinthus Biotherapeutics plc (BRNS) - Net Assets
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has net assets worth $84.56 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.20 Million) and total liabilities ($24.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Barinthus Biotherapeutics plc total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $84.56 Million |
| % of Total Assets | 77.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11.27 |
Barinthus Biotherapeutics plc - Net Assets Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's net assets have evolved over time, based on quarterly financial data. Also explore Barinthus Biotherapeutics plc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual net assets of Barinthus Biotherapeutics plc from 2019 to 2024. For live valuation and market cap data, see Barinthus Biotherapeutics plc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $130.13 Million | -30.41% |
| 2023-12-31 | $187.00 Million | -23.11% |
| 2022-12-31 | $243.20 Million | -3.71% |
| 2021-12-31 | $252.56 Million | +8125.48% |
| 2020-12-31 | $-3.15 Million | +85.75% |
| 2019-12-31 | $-22.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Barinthus Biotherapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19977873900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $-25.87 Million | -19.89% |
| Other Components | $393.56 Million | 302.67% |
| Total Equity | $130.03 Million | 100.00% |
Barinthus Biotherapeutics plc Competitors by Market Cap
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vikas EcoTech Limited
NSE:VIKASECO
|
$26.59 Million |
|
Morgan Sindall Group PLC
LSE:MGNS
|
$26.59 Million |
|
Starteck Finance Limited
NSE:STARTECK
|
$26.59 Million |
|
Carimin Petroleum Bhd
KLSE:5257
|
$26.61 Million |
|
White Horse Bhd
KLSE:5009
|
$26.58 Million |
|
Hotel Royal Chihpen
TWO:5704
|
$26.57 Million |
|
Cue Biopharma
NASDAQ:CUE
|
$26.56 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
$26.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Barinthus Biotherapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 186,784,000 to 130,029,000, a change of -56,755,000 (-30.4%).
- Net loss of 61,074,000 reduced equity.
- New share issuances of 2,163,000 increased equity.
- Other comprehensive income decreased equity by 2,553,000.
- Other factors increased equity by 4,709,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.07 Million | -46.97% |
| Share Issuances | $2.16 Million | +1.66% |
| Other Comprehensive Income | $-2.55 Million | -1.96% |
| Other Changes | $4.71 Million | +3.62% |
| Total Change | $- | -30.39% |
Book Value vs Market Value Analysis
This analysis compares Barinthus Biotherapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.87 | $0.65 | x |
| 2020-12-31 | $-0.45 | $0.65 | x |
| 2021-12-31 | $6.78 | $0.65 | x |
| 2022-12-31 | $6.36 | $0.65 | x |
| 2023-12-31 | $4.87 | $0.65 | x |
| 2024-12-31 | $3.30 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Barinthus Biotherapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -408.00%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.23x
- Recent ROE (-46.97%) is below the historical average (-17.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -302.84% | 0.36x | 0.00x | $-18.48 Million |
| 2020 | 0.00% | -367.27% | 0.10x | 0.00x | $-17.35 Million |
| 2021 | -20.17% | -18979.48% | 0.00x | 1.11x | $-76.08 Million |
| 2022 | 2.20% | 11.95% | 0.17x | 1.11x | $-18.95 Million |
| 2023 | -39.27% | -9145.51% | 0.00x | 1.15x | $-92.03 Million |
| 2024 | -46.97% | -408.00% | 0.09x | 1.23x | $-74.08 Million |
Industry Comparison
This section compares Barinthus Biotherapeutics plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Barinthus Biotherapeutics plc (BRNS) | $84.56 Million | 0.00% | 0.29x | $26.58 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more